Published in final edited form as:

ACS Chem Biol. 2012 October 19; 7(10): 1641–1646. doi:10.1021/cb300233y.

Potentiation of the Kv1 family K⁺ channel by cortisone analogs

Yaping Pan¹, Elena J. Levin¹, Matthias Quick^{2,3}, and Ming Zhou^{1,*}

¹Department of Physiology and Cellular Biophysics, College of Physicians and Surgeons, Columbia University, 630 West 168th Street, New York, NY 10032

²Department of Psychiatry and Center for Molecular Recognition, Columbia University, 630 West 168th Street, New York, NY 10032

³New York State Psychiatric Institute, Division of Molecular Therapeutics, 1051 Riverside Drive, New York, NY 10032

Abstract

The Kv1 family voltage-dependent K⁺ channels are essential for termination of action potentials in neurons and myocytes. These channels form a stable complex with their beta subunits (Kvβ), some of which inhibit channel activity. Cortisone potentiates Kv1 channel by binding to Kvβ and promoting its dissociation from the channel, but its half-maximum effective concentration is ~46 μM. To identify corticosteroids that are more efficient than cortisone, we examined 25 cortisone analogs and found that fluticasone propionate potentiates channel current with a half-maximum effective concentration (EC₅₀) of 37 ± 1.1 nM. Further studies showed that fluticasone propionate potentiates channel current by inducing dissociation of Kvβ, and docking of fluticasone propionate into the cortisone binding site reveals potential interactions that enhance the EC₅₀ value. Thus, fluticasone propionate provides a starting point for rational design of more efficient small-molecule compounds that increase Kv1 activity and affect the integrity of the Kv1-Kvβ complex.

Voltage-dependent potassium channels (Kv) are tetrameric integral membrane proteins that allow K⁺ to flow out of a cell upon membrane depolarization. The efflux of K⁺ brings the membrane potential back to the resting value, thus reducing the cell's excitability. In humans, reduced Kv1 channel activity due to heterozygous loss-of-function mutations has been linked directly to epilepsy and atrial fibrillation (1;2), and in theory, Kv1 channel openers could decrease hyperexcitability found in these diseases. However, currently there are no clinically useful Kv1 channel openers.

Kv1 channels assemble with a cytosolic beta subunit (Kvβ) to form a stable complex with a stoichiometry of (Kv1)₄(Kvβ1)₄ (3–8). The functions of Kvβ are at least threefold. First, Kv1 and Kvβ associate in the endoplasmic reticulum (ER) at an early stage of channel biosynthesis (9;10), and an intact Kv1-Kvβ complex is exported to its final destination on the plasma membrane more efficiently than Kv1 alone (9;11;12). Second, Kvβ has a large impact on channel activities. There are three mammalian Kvβ genes, Kvβ1–3 (13). Kvβ1 and Kvβ3 have flexible N-termini that block the channel (14), a mechanism commonly known as N-type inactivation (15;16). Third, and perhaps most intriguingly, all three Kvβs share a highly conserved and structured core region (17;18) that acts as a functional aldo-keto reductase with NADPH as a cofactor (19–21). Oxidation of the NADPH on the conserved core of Kvβ reduces N-type inactivation (19;20). However, the physiological function of this redox regulated channel activity remains a mystery.

*Correspondence to M.Z. (mz2140@columbia.edu).

Although the Kv1-Kv β complex is stable under physiological conditions, cortisone induces dissociation of Kv β from the channel by binding to Kv β at a site close to the Kv1-Kv β interface (22). When cortisone was applied to the Kv1-Kv β 1 complex, a significant increase of current was observed due to loss of N-type inactivation, and the effect had a half maximum effective concentration (EC₅₀) of $46 \pm 1.1 \mu\text{M}$ (22). In addition to being a Kv1 channel opener, cortisone could be a chemical knockout reagent to facilitate investigation of Kv β functions in physiology. Eliminating Kv β after the Kv1-Kv β complex is already delivered to its intended position has an advantage over genetic knockout of Kv β genes, because the chemical approach will likely preserve the location and surface expression level of the channel. As the first step to improving the affinity and efficacy of cortisone, we examined how cortisone analogs affect channel current.

Modulation of Kv1 current by cortisone analogs

A total of 25 commercially available cortisone analogs were examined and the analogs were perfused to inside-out patches expressing Kv1.1 and Kv β 1. A single concentration of 500 μM was used for the majority of the analogs, except for cortisone 21-acetate and fluticasone propionate, which were 100 and 20 μM in the initial test due to low solubility. Change in channel current after perfusion of a compound was quantified and plotted in Figure 1. Typical currents before and after perfusion are shown for vehicle control (Figure 1a), cortisone (Figure 1b), cortisone 21-acetate (Figure 1c), and fluticasone propionate (Figure 1d). Only two compounds, cortisone 21-acetate and fluticasone propionate, potentiated channel current significantly (Figure 1e and f).

To further characterize the effect of the two compounds, channel current was recorded at various concentrations of either cortisone 21-acetate or fluticasone propionate and dose-response profiles were constructed (Figure 1g), which led to an estimated EC₅₀ of $9.0 \pm 1.1 \mu\text{M}$ and $37 \pm 1.1 \text{ nM}$ for cortisone 21-acetate and fluticasone propionate, respectively. Although the EC₅₀ value for cortisone 21-acetate is slightly lower than that of cortisone (46 μM), that of fluticasone propionate is substantially lower.

Mechanism of Kv1 current potentiation

To examine if potentiation of current in the presence of cortisone 21-acetate or fluticasone propionate is mediated by the conserved core of Kv β 1, a mutant Kv1.1, Kv1.1-inact was tested. The Kv1.1-inact construct contains the inactivation gate of Kv β 1 spliced onto the N-terminus of Kv1.1, and therefore lacks the core domain while still generating inactivating currents similar to these produced by co-expression Kv1.1 and Kv β 1 (19;22) (Figure 2a). When perfused to the inside-out patches expressing Kv1.1-inact, neither cortisone 21-acetate nor fluticasone propionate increased current significantly more than the vehicle control (Figure 2a and d), indicating that both compounds potentiate channel current through the conserved core of Kv β 1.

Although cortisone 21-acetate has an identical pregnene ring to that of cortisone, fluticasone propionate does not and this raises the question of whether the two compounds bind to Kv β 1 similarly to cortisone. A previous study showed that Kv β provides a deep binding pocket to accommodate the pregnene ring of cortisone, and a mutation in the binding pocket, V245R, eliminates cortisone binding (22). We therefore examined how the compounds affect the V245R mutant protein. Both compounds induced a small change in channel current, which was not significantly different from the vehicle controls (Figure 2b and d). These results confirmed that the two compounds likely interact with Kv β 1 at the same site where cortisone binds.

To find out if cortisone 21-acetate or fluticasone propionate potentiate channel current by promoting dissociation of Kv β 1, we tested the two compounds on the Kv β 1-Kv1.1 chimera, in which Kv β 1 was spliced to the N-terminus of Kv1.1 and thus cannot dissociate from the channel. The chimera was not potentiated by either of the compounds, indicating that both compounds modify channel current by inducing dissociation of Kv β 1 (Figure 2c and d).

To further demonstrate that cortisone 21-acetate or fluticasone propionate binds to Kv β 1 at the same site as cortisone, we used a scintillation proximity assay (SPA) to measure the binding of radio-labeled cortisone to Kv β . By competing with the labeled cortisone with various concentrations of unlabeled cortisone, an equilibrium inhibition constant (K_i) was obtained at $30 \pm 10 \mu\text{M}$ (Figure 2e). The value is comparable to the EC_{50} values obtained from measuring dissociation of Kv β from the channel (22). None labeled cortisone 21-acetate ($250 \mu\text{M}$) and fluticasone propionate ($250 \mu\text{M}$) reduced cortisone binding by $95 \pm 0.2\%$ and $98 \pm 0.1\%$, respectively (Figure 2f). These data provide another line of evidence that the two identified cortisone analogs bind to the same binding pocket as cortisone.

Interactions of fluticasone propionate with Kv β

To determine how fluticasone propionate interacts with Kv β to achieve an EC_{50} almost 1000 fold smaller than that of cortisone, we attempted to obtain a structure of fluticasone propionate in complex with Kv β , but our repeated efforts were unsuccessful. We therefore used the program AutoDock Vina (23) to model fluticasone propionate into the known binding site for cortisone. The lowest energy conformation is shown in Figure 3a. As a control, an identical docking protocol was performed with cortisone, which predicted a conformation for the ligand with a $0.9 \text{ \AA}$ root mean square deviation from the crystallographically-determined position (Figure 3a, right). While the fluticasone propionate model suggests some possible electrostatic interactions with the protein not present with cortisone, including a hydrogen bond between a fluorine atom and residue Lys44 on the protein, a more significant contributor to the lower EC_{50} of fluticasone propionate may be the improved shape complementarity between the ligand and binding site. The fluorine atoms on fluticasone propionate appear to increase the area of the interacting surface between the ligand and the binding pocket (Figure 3a). Also, the additional double bond between carbons 1 and 2 introduces a kink to the steroid rings that better matches the sock-like shape of the cavity (Figure 3b).

As shown in Figure 3c, cortisone's position in the binding pocket on Kv β results in steric clashes between the D ring and the hydroxyl group on the 17th position and residues 75 and 76 on the T1 domain of the channel, leading to dissociation of Kv β . Fluticasone propionate has two large substitutions at the 17th position, resulting in an increased volume protruding into the Kv β /T1 interface. The more severe steric clash generated by the presence of fluticasone propionate may contribute to its lower apparent EC_{50} .

Cortisone and fluticasone propionate potentiate Kv1 current in HEK cells

Since all electrophysiological studies have been performed on inside-out patches with cortisone and fluticasone propionate being perfused directly to the intracellular side of the membrane, as a first step to demonstrate the utility of these compounds, we examined them on HEK293 cells stably transfected with Kv1.1 and Kv β 1. The whole-cell patch clamp configuration was employed and the compounds were applied to the extracellular side of a cell. Cortisone and fluticasone propionate both potentiated channel current significantly (Figure 4a–d), indicating that both could be effective on primary cells or in an organism.

Discussion

In summary, we have found that fluticasone propionate potentiates Kv1 current by promoting dissociation of Kv β 1. Compounds that target Kv β have specificity to Kv1 channels because of exclusive assembly between Kv1 and Kv β (3;8;24). The EC₅₀ of the fluticasone propionate effect is significantly smaller than cortisone, and the improvement can be attributed, at least in part, to favorable interactions between fluorine on the ligand and a positively charged residue on the protein, and to better shape complementarity between the ligand and the binding pocket. It is intriguing that although fluticasone propionate has a much lower EC₅₀ value, its maximum effect on ΔI_{ss} is smaller than that of cortisone (Figure 1d, 1f). Nevertheless, all three corticosteroids are highly effective in potentiating channel current, and fluticasone propionate represents an improved starting point over cortisone for further structure-activity studies to identify compounds that have better efficiency to potentiate Kv1 channel current.

Fluticasone propionate has long been used as an inhaled drug to treat asthma and because it is an analog of corticosteroid, its mechanism of action is thought to be related to the regulation of the immune response. However, the current study suggests that fluticasone propionate may play an additional role: Kv1 and Kv β 1 are both highly expressed on airway smooth muscle cells (25), and the inhaled fluticasone propionate could potentiate these channels in the smooth muscle, which would lead to relaxation of the smooth muscle cells and relief of airway obstruction.

METHODS

Molecular biology and electrophysiological recordings

For oocyte expression, the full length cDNA of rat Kv1.1 (accession number NM_173095) or that of rat Kv β 1 (accession number NM_017303) was cloned into a modified pBluescript vector (a gift from Dr. Mark Sonders, Columbia University) between the KpnI and EcoRI sites for *in vitro* transcription. The Kv1.1-inact or the Kv β 1-Kv1.1 connected chimera was generated by splicing the DNA sequence encoding residues 1 to 70 of Kv β 1 or the full length of Kv β 1 onto that of Kv1.1 (encoding residues 2 to 495-stop) by the overlapping PCR method, respectively. The PCR products were then ligated into the same pBluescript vector. Point mutations were made using the QuikChange kit (Agilent Technologies). mRNA was prepared by *in vitro* T7 polymerase transcription after DNA was linearized with NotI. mRNAs were purified using the Trizol reagent (Invitrogen Inc.) and injected into *Xenopus* oocytes for channel expression. For co-expression, mRNAs of Kv1.1 and Kv β 1 were mixed and injected together into oocytes. The inside-out patch clamp recordings followed the same procedures detailed in ref (19;20).

To prepare HEK293 cells stably transfected with Kv1.1 and Kv β 1, the cDNA of Kv1.1 was cloned into a pcDNA5/FRT/TO vector and that of Kv β 1 was cloned into a pIRESpuro vector (both from Invitrogen). The Flp-in HEK293 cell line was used for transfections and the stably transfected cell lines were maintained under three antibiotics, blasticidin (final concentration of 15 μ g/ml), puromycin (final concentration of 2 μ g/ml) and hygromycin B (final concentration of 100 μ g/ml). Tetracycline at the final concentration of 2 μ g/ml was added 18–24 hr before patch clamp experiments to induce channel expression. The pipette solution contained (in mM): K-aspartate 110, MgCl₂ 1, CaCl₂ 1, EGTA 11, HEPES 10, and ATP-K₂ 5 at pH 7.3. The external solution contained (in mM): NaCl 132, KCl 4.8, MgCl₂ 1.2, CaCl₂ 2, HEPES 10 at pH 7.4, and glucose 5. K⁺ currents were elicited by holding the patch at -80 mV and stepping to +60 mV for 400 msec.

Cortisone analogs were first dissolved in dimethylsulfoxide (DMSO) and then diluted into the internal buffer to the desired concentrations. The final concentration of DMSO was kept at 1% (v/v) for all analogs. Kv β 1 has a cysteine residue at position 7 that can be oxidized on inside-out patches to affect channel inactivation (26). To eliminate concerns that the effect could be due to cysteine oxidation, we mutated the 7th position cysteine to an alanine, for Kv β 1 and Kv β 1-Kv1.1. ΔI_{ss} , the increase of steady-state current as a fraction of the initial inactivating current, was calculated by the following equation:

$$\Delta I_{ss} = \frac{I_{ss, A} - I_{ss, B}}{I_{peak, B} - I_{ss, B}}$$

where $I_{ss, A}$ and $I_{ss, B}$ are the steady-state currents, measured at 200 msec after depolarization, after and before compounds perfusion, respectively. $I_{peak, B}$ is the peak current amplitude before compounds perfusion. All chemicals were purchased from Sigma.

Scintillation proximity assay

The core domain of Kv β 2 was expressed and purified as described in reference (20). Kv β 2 was used instead of Kv β 1 because it is more stable biochemically, and the amino acid sequences of the proteins are more than 80% identical. It has been demonstrated previously that cortisone can bind to both Kv β cores, and the binding promotes dissociation (22). The Kv β 2 core used in the binding study carries a mutation, W272A, which eliminates a secondary binding site that is not involved in dissociation of Kv β (22).

Binding of 80 nM [1,2,6,7-³H]cortisone (90 Ci/mmol; American Radiolabeled Chemicals, Inc.) to 1 μ g purified protein was measured in 100 μ L of 50 mM Tris/Mes, pH 8.0, 300 mM KCl, 10% [w/v] glycerol, 100 μ M tris(2-carboxyethyl)phosphine (TCEP) containing 2.5 mg Cu²⁺-coated YSi-SPA beads/mL (Perkin Elmer) for 4 hr at 4 °C. Reactions were performed in 96-well white wall clear-bottom plates and assayed in a Wallac photomultiplier tube MicroBeta^{TM} counter. Non-proximity background signals were determined for all conditions tested in the presence of 400 mM imidazole and used to determine the specific counts per minute (cpm). Appropriate concentrations of the indicated compounds were added to the reactions as indicated. All conditions were tested in triplicate.

Docking

The model of fluticasone propionate was built using the PRODRG server (27). Coordinates from a structure of the unliganded Kv β 1/T1 complex, PDB entry 1EXB (3), were used to build the Kv β tetramer. Hydrogens and Gasteiger charges were added to ligand and receptor using AutoDockTools (28), and the docking was performed using AutoDock Vina (23). Figures of the protein and ligand structures were prepared in PyMol (Schrödinger, San Diego, CA).

Reagents

Twenty five cortisone analogs were purchased from Sigma, including cortisone 21-acetate (C3130), fluticasone propionate (F9428), adrenosterone (284998), prednisone (286990), hydrocortisone (H4001), prednisolone (P6004), corticosterone (C2505), androsterone (219010), aldosterone (A9477), 6 α -methyl-prednisolone (M0639), betamethasone (B7005), dexamethasone (861871), progesterone (P8783), 17 α -hydroxyprogesterone (H5752), budonide (B7777), beclomethasone dipropionate (B3022), testosterone (T1500), epitestosterone (E5878), 1,4-androstadiene-3,17-dione (A7505), 5 α -androst-3 β -ol (A2480), 5 α -androst-16-en-3-one (A8008), 5 α -androst-3 β -ol-16-one (A7386), 5 α -

androst-16-en-3 α -ol (A7883), cyproterone acetate (C3412), and diflorasone diacetate (D8286).

Data statistics

The Origin 7.5 software package was used for statistical analysis of the data. The results are expressed as mean $\pm$ standard error of mean (s.e.m.). One-way analysis of variance (ANOVA) was used to assess changes of a mean value. A value of $p < 0.05$ was considered significant.

Accession codes

Coordinates and structure factors of Kv β 2-cortisone (22) (3EAU) and T1-Kv β 2 complex (3) (1EXB) were downloaded from PDB. GenBank identifiers: rat Kv1.1, NM_173095; rat Kv β 1, NM_017303.

References

- Adelman JP, Bond CT, Pessia M, Maylie J. Episodic ataxia results from voltage-dependent potassium channels with altered functions. *Neuron*. 1995; 15:1449–1454. [PubMed: 8845167]
- Olson TM, Alekseev AE, Liu XK, Park S, Zingman LV, Bienengraeber M, Sattiraju S, Ballew JD, Jahangir A, Terzic A. Kv1.5 channelopathy due to KCNA5 loss-of-function mutation causes human atrial fibrillation. *Hum. Mol. Genet.* 2006; 15:2185–2191. [PubMed: 16772329]
- Gulbis JM, Zhou M, Mann S, MacKinnon R. Structure of the cytoplasmic beta subunit-T1 assembly of voltage-dependent K⁺ channels. *Science*. 2000; 289:123–127. [PubMed: 10884227]
- Long SB, Campbell EB, MacKinnon R. Crystal structure of a mammalian voltage-dependent *Shaker* family K⁺ channel. *Science*. 2005; 309:897–903. [PubMed: 16002581]
- Sokolova O, Accardi A, Gutierrez D, Lau A, Rigney M, Grigorieff N. Conformational changes in the C terminus of *Shaker* K⁺ channel bound to the rat Kvbeta2-subunit. *Proc. Natl. Acad. Sci. U. S. A.* 2003; 100:12607–12612. [PubMed: 14569011]
- Scott VE, Rettig J, Parcej DN, Keen JN, Findlay JB, Pongs O, Dolly JO. Primary structure of a beta subunit of alpha-dendrotoxin-sensitive K⁺ channels from bovine brain. *Proc. Natl. Acad. Sci. U. S. A.* 1994; 91:1637–1641. [PubMed: 8127858]
- Yu W, Xu J, Li M. NAB domain is essential for the subunit assembly of both alpha-alpha and alpha-beta complexes of *shaker*-like potassium channels. *Neuron*. 1996; 16:441–453. [PubMed: 8789959]
- Sewing S, Roeper J, Pongs O. Kv beta 1 subunit binding specific for *shaker*-related potassium channel alpha subunits. *Neuron*. 1996; 16:455–463. [PubMed: 8789960]
- Shi G, Nakahira K, Hammond S, Rhodes KJ, Schechter LE, Trimmer JS. Beta subunits promote K⁺ channel surface expression through effects early in biosynthesis. *Neuron*. 1996; 16:843–852. [PubMed: 8608002]
- Nagaya N, Papazian DM. Potassium channel alpha and beta subunits assemble in the endoplasmic reticulum. *J. Biol. Chem.* 1997; 272:3022–3027. [PubMed: 9006951]
- Accili EA, Kuryshev YA, Wible BA, Brown AM. Separable effects of human Kvbeta1.2 N- and C-termini on inactivation and expression of human Kv1.4. *J. Physiol.* 1998; 512(Pt 2):325–336. [PubMed: 9763623]
- Gu C, Jan YN, Jan LY. A conserved domain in axonal targeting of Kv1 (*Shaker*) voltage-gated potassium channels. *Science*. 2003; 301:646–649. [PubMed: 12893943]
- Pongs O, Leicher T, Berger M, Roeper J, Bähring R, Wray D, Giese KP, Silva AJ, Storm JF. Functional and molecular aspects of voltage-gated K⁺ channel beta subunits. *Ann. N. Y. Acad. Sci.* 1999; 868:344–355. [PubMed: 10414304]
- Rettig J, Heinemann SH, Wunder F, Lorra C, Parcej DN, Dolly JO, Pongs O. Inactivation properties of voltage-gated K⁺ channels altered by presence of beta-subunit. *Nature*. 1994; 369:289–294. [PubMed: 8183366]
- Hoshi T, Zagotta WN, Aldrich RW. Biophysical and molecular mechanisms of *Shaker* potassium channel inactivation. *Science*. 1990; 250:533–538. [PubMed: 2122519]

16. Zagotta WN, Hoshi T, Aldrich RW. Restoration of inactivation in mutants of *Shaker* potassium channels by a peptide derived from ShB. *Science*. 1990; 250:568–571. [PubMed: 2122520]
17. Chouinard SW, Wilson GF, Schlimgen AK, Ganetzky B. A potassium channel beta subunit related to the aldo-keto reductase superfamily is encoded by the *Drosophila* hyperkinetic locus. *Proc. Natl. Acad. Sci. U. S. A.* 1995; 92:6763–6767. [PubMed: 7542775]
18. McCormack T, McCormack K. *Shaker* K⁺ channel beta subunits belong to an NAD(P)H-dependent oxidoreductase superfamily. *Cell*. 1994; 79:1133–1135. [PubMed: 8001150]
19. Pan Y, Weng J, Cao Y, Bhosle R, Zhou M. Functional coupling between the Kv1.1 channel and an aldo-keto reductase Kvbeta1. *J. Biol. Chem.* 2008; 283:8634–8642. [PubMed: 18222921]
20. Weng J, Cao Y, Moss N, Zhou M. Modulation of voltage-dependent *shaker* family potassium channels by an aldo-keto reductase. *J. Biol. Chem.* 2006; 281:15194–15200. [PubMed: 16569641]
21. Tipparaju SM, Barski OA, Srivastava S, Bhatnagar A. Catalytic mechanism and substrate specificity of the beta-subunit of the voltage-gated potassium channel. *Biochemistry*. 2008; 47:8840–8854. [PubMed: 18672894]
22. Pan Y, Weng J, Kabaleeswaran V, Li H, Cao Y, Bhosle RC, Zhou M. Cortisone dissociates the *Shaker* family K⁺ channels from their beta subunits. *Nat. Chem. Biol.* 2008; 4:708–714. [PubMed: 18806782]
23. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. *J. Comput. Chem.* 2010; 31:455–461. [PubMed: 19499576]
24. Rhodes KJ, Strassle BW, Monaghan MM, Bekele-Arcuri Z, Matos MF, Trimmer JS. Association and colocalization of the Kvbeta1 and Kvbeta2 beta-subunits with Kv1 alpha-subunits in mammalian brain K⁺ channel complexes. *J. Neurosci.* 1997; 17:8246–8258. [PubMed: 9334400]
25. Adda S, Fleischmann BK, Freedman BD, Yu M, Hay DW, Kotlikoff MI. Expression and function of voltage-dependent potassium channel genes in human airway smooth muscle. *J. Biol. Chem.* 1996; 271:13239–13243. [PubMed: 8662756]
26. Ruppersberg JP, Stocker M, Pongs O, Heinemann SH, Frank R, Koenen M. Regulation of fast inactivation of cloned mammalian IK(A) channels by cysteine oxidation. *Nature*. 1991; 352:711–714. [PubMed: 1908562]
27. Schuttelkopf AW, van Aalten DM. PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. *Acta Crystallogr. D. Biol. Crystallogr.* 2004; 60:1355–1363. [PubMed: 15272157]
28. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. *J. Comput. Chem.* 2009; 30:2785–2791. [PubMed: 19399780]

Figure 1.

Potentiation of Kv1 current by cortisone analogs. (a–d) Current traces of Kv1.1 co-expressed with Kvβ1 before (black) and after (red) perfusion of the vehicle (1% DMSO, a), 500 μM cortisone (b), 100 μM cortisone 21-acetate (c), or 20 μM fluticasone propionate (d). Scale bars represent 300 pA and 10 ms. (e) Chemical structures of cortisone, cortisone 21-acetate, and fluticasone propionate. (f) ΔI_{ss} after perfusion of the vehicle (1% DMSO), cortisone and 25 cortisone analogs. (g) Normalized ΔI_{ss} induced by different concentrations of cortisone (○), cortisone 21-acetate (□), and fluticasone propionate (Δ) in Kv1.1 co-expressed with Kvβ1. The solid curves are the dose-response function fit to the data points. Error bars are s.e.m. from 3 to 13 patches.

Figure 2.

Mechanism of channel potentiation by cortisone 21-acetate and fluticasone propionate. (a–c) Current traces of Kv1.1-inact (a), Kv1.1 co-expressed with Kv β 1V245R (b), and Kv β 1-Kv1.1 chimera (c) before (black) and after (red) perfusion of 100 μ M cortisone 21-acetate (left panel) or 20 μ M fluticasone propionate (right panel). Scale bars represent 300 pA and 10 ms. (d) ΔI_{ss} after perfusion of the vehicle (1% DMSO), cortisone 21-acetate, or fluticasone propionate. Error bars are s.e.m. from 3 to 5 patches. (e) SPA-based ^{3} H-cortisone equilibrium binding with increasing concentrations of cortisone. The solid curve corresponds to data fit with a single-site binding isotherm. Error bars are s.e.m. from 3 measurements. (f) SPA-based ^{3} H-cortisone equilibrium binding without or with cortisone analogs. Error bars are s.e.m. from 3 measurements.

Figure 3.

Comparison of cortisone and fluticasone propionate binding to Kvβ. (a) Surface representation of the Kvβ binding site shown with either the docking model of fluticasone propionate (left) or cortisone (right) from the crystal structure (gray), overlaid with a docking model produced by the same protocol used for the fluticasone propionate model (black). (b) Fluticasone propionate (left) and cortisone (right) shown as spheres. (c) The location of the binding site on the Kvβ tetramer (blue) shown in complex with the channel T1 domain (teal, PDB #1EXB). The inset shows expected clashes between cortisone (gray) and fluticasone propionate (black) and residues 75–76 on the T1 domain.

Figure 4.

Cortisone and fluticasone propionate potentiate Kv1 current in HEK cells. Current traces of Kv1.1 co-expressed with Kvβ1 from whole-cell patch clamped HEK cells before (black) and after (red) perfusion of the vehicle (1% DMSO, a), 200 μM cortisone (b), or 20 μM fluticasone propionate (c). Scale bars represent 300 pA and 30 ms. (d) ΔI_{ss} after perfusion of the vehicle (1% DMSO), cortisone, or fluticasone propionate. Error bars are s.e.m. from 3 to 5 patches.